Serum erythropoietin increase in patients receiving adjuvant therapy with 5-fluorouracil and leucovorin.
High-dose anticancer drugs have been shown to induce an increase in serum erythropoietin (sEpo) levels not mediated by hypoxia. In this study, sEpo was assessed in seven patients who had been administered a course of 5-day leucovorin-modulated 5-fluorouracil (5-FU-LV) as an adjuvant therapy after the removal of colon cancer. During this study, the mean hemoglobin (Hb) concentration stayed at a constant level, peripheral blood (PB) reticulocytes showed an early, sharp decline, and sEpo levels progressively increased for 15 days after the start of chemotherapy. These results appear to indicate that the increase in sEpo, which was not related to anemia, may have followed from the administration of a cytotoxic drug at doses used in routine, clinical practice.
Department of Internal Medicine, University of Genoa, Italy.
A
A
Cerruti
G
G
Castello
E
E
Balleari
G
G
Bogliolo
R
R
Lerza
I
I
Pannacciulli
D000368:Aged; D003110:Colonic Neoplasms / Q000188:drug therapy; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000097:blood*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D017701:Reticulocyte Count; D013997:Time Factors
D004921:Erythropoietin; D002955:Leucovorin; D005472:Fluorouracil